

Notice of Annual General Meeting

CONDUCT OF ANNUAL GENERAL MEETING IN LIGHT OF COVID-19 OUTBREAK

In view of the elevated safe distancing measures imposed by the Singapore Government due to the COVID-19 outbreak, Raffles Medical Group Ltd (the “**Company**”) will be conducting the 31st Annual General Meeting (the “**AGM**”) of the Company wholly by electronic means in accordance with the COVID-19 (Temporary Measures) (Alternative Arrangements for Meetings for Companies, Variable Capital Companies, Business Trusts and Debenture Holders) Order 2020 (the “**Order**”) and the Joint Statement of the Accounting and Corporate Regulatory Authority, Monetary Authority of Singapore and Singapore Exchange Regulation issued on 13 April 2020 (and updated on 27 April 2020) titled “Additional Guidance on the Conduct of General Meetings During Elevated Safe Distancing Period” (the “**Joint Guidance**”).

Shareholders of the Company (“**Shareholders**”) should take note of the following arrangements for the AGM:

- (a) **Attendance in Person:** The AGM will be conducted only by electronic means and Shareholders will not be able to physically attend the AGM. The proceedings of the AGM will be broadcast through a “live” audio-visual webcast (accessible via mobile phones, tablets or computers) and “live” audio-only stream (accessible via telephone). Please pre-register for the “live” audio-visual webcast or “live” audio-only stream if you wish to attend the AGM.
- (b) **“Live” Audio and Video Webcast:** All Shareholders and investors holding shares through Central Provident Fund (“**CPF**”) and Supplementary Retirement Scheme (“**SRS**”) (“**CPF/SRS Investors**”) who wish to follow the proceedings of the AGM through the “live” audio-visual webcast or “live” audio-only stream must **pre-register online at <https://www.meetings.vision/rmg-agm-registration> by Tuesday, 23 June 2020, 10.30 a.m. Singapore time** for verification purposes. Following successful verification, details on how to join the “live” audio-visual webcast or “live” audio-only stream will be sent to you by **Thursday, 25 June 2020, 12.00 p.m. Singapore time** at the email specified in your pre-registration details. Investors holding shares through relevant intermediaries (as defined in Section 181 of the Companies Act (Chapter 50 of Singapore)) (“**Investors**”) (other than CPF/SRS Investors) will not be able to pre-register at <https://www.meetings.vision/rmg-agm-registration> for the “live” audio-visual webcast or “live” audio-only stream of the AGM. If they wish to follow the proceedings of the AGM through the “live” broadcast of the AGM, they should instead approach their respective relevant intermediary as soon as possible in order to make the necessary arrangements.
- (c) **Submission of Questions:** Shareholders and Investors will not be able to ask questions “live” via the audio-visual webcast or audio-only stream. All Shareholders and Investors can submit questions relating to the business of the AGM **up until Tuesday, 23 June 2020, 10.30 a.m. Singapore time** (being 72 hours before the time appointed for the holding of the AGM) either (i) only for Shareholders and CPF/SRS Investors who pre-register to follow the proceedings of the AGM through the “live” audio-visual webcast or “live” audio-only stream, via the pre-registration website at <https://www.meetings.vision/rmg-agm-registration>, (ii) via post, to be deposited at the office of M & C Services Private Limited (the “**Share Registrar**”) at 112 Robinson Road #05-01 Singapore 068902 or (iii) via email to investorrelations@rafflesmedical.com.

When sending your questions by email or post, please also provide the Company with: (i) your full name; (ii) your address; and (iii) the manner in which you hold shares in the Company (e.g. via CDP, CPF or SRS).

The Company will endeavour to respond to substantial and relevant questions either prior to the AGM (via an announcement on SGXNET and the Company’s website) or during the AGM. The Company will also publish the minutes of the AGM on SGXNET and the Company’s website. The minutes will include the Company’s responses to the questions from Shareholders/Investors which are addressed during the AGM.

Notice of Annual General Meeting

- (d) **Voting Solely via Appointing Chairman as Proxy (Submit a Proxy Form):** Shareholders will only be able to vote at the AGM by appointing the Chairman of the AGM as proxy to vote on their behalf. Duly completed Proxy Forms must be deposited with the Company (i) via post, to be deposited at the office of the Company's Share Registrar at 112 Robinson Road #05-01 Singapore 068902 or (ii) via email to gpb@mncsingapore.com (by enclosing a clear scanned completed and signed Proxy Form) and must be received by the Company by **Tuesday, 23 June 2020, 10.30 a.m. Singapore time** (being 72 hours before the time appointed for the holding of the AGM). Proxy Forms can be downloaded from SGXNET, the Company's website or the pre-registration website. In the Proxy Form, a Shareholder should specifically direct the proxy on how he is to vote for or vote against (or abstain from voting on) the resolutions to be tabled at the AGM. If no specific direction as to voting on a given resolution is given, the appointment of the Chairman of the AGM as proxy for that resolution shall be treated as invalid. **In view of the COVID-19 situation, we strongly encourage Shareholders to submit the completed and signed Proxy Form via email.**
- (e) **Voting by Investors holding shares through relevant intermediaries (including CPF/SRS Investors):** Investors (including CPF/SRS Investors) that wish to vote should not make use of the Proxy Form and should instead approach their respective relevant intermediary as soon as possible to specify voting instructions. CPF/SRS Investors who wish to vote should approach their respective CPF Agent Bank/SRS Operator by **Tuesday, 16 June 2020, 5.00 p.m. Singapore time**, to ensure that their votes are submitted.

IMPORTANT DATES AND TIMES

DATE / TIME	ACTIONS
From Thursday, 4 June 2020, 6.00 p.m. Singapore time	Shareholders and CPF/SRS Investors may begin to pre-register at https://www.meetings.vision/rmg-agm-registration for the "live" audio-visual webcast or "live" audio-only stream of the AGM proceedings.
By Tuesday, 16 June 2020, 5.00 p.m. Singapore time	Deadline for CPF/SRS Investors that wish to vote to approach their respective CPF Agent Bank/SRS Operator to submit their votes.
By Tuesday, 23 June 2020, 10.30 a.m. Singapore time	<p>Deadline for Shareholders and CPF/SRS Investors to:</p> <p>(a) pre-register online at https://www.meetings.vision/rmg-agm-registration to attend the AGM; and</p> <p>(b) submit questions relating to the business of the AGM either via (i) the pre-registration website at https://www.meetings.vision/rmg-agm-registration (ii) post, to be deposited at the office of the Company's Share Registrar at 112 Robinson Road #05-01 Singapore 068902 or (iii) email to investorrelations@rafflesmedical.com.</p> <p>Deadline for Shareholders that wish to vote to deposit completed Proxy Forms either by (i) post to the office of the Company's Share Registrar at 112 Robinson Road #05-01 Singapore 068902 or (ii) email to gpb@mncsingapore.com.</p> <p>In view of the COVID-19 situation, we strongly encourage Shareholders to submit the completed and signed Proxy Form via email.</p>
By Thursday, 25 June 2020, 12.00 p.m. Singapore time	Verified Shareholders/Investors will receive an email with details on how to attend the AGM (" Confirmation Email "). The Confirmation Email will contain user ID and password details, as well as the link to access the "live" audio-visual webcast or a telephone number and a conference code to access the "live" audio-only stream of the AGM proceedings.

Notice of Annual General Meeting

DATE / TIME	ACTIONS
From Thursday, 25 June 2020 between 12.00 p.m. and 7.00 p.m. Singapore time, to Friday, 26 June 2020 between 8.00 a.m. and 10.00 a.m. Singapore time	Shareholders/Investors that have pre-registered by Tuesday, 23 June 2020, 10.30 a.m. Singapore time, but have not received any Confirmation Email should contact the Company's Share Registrar at +65 6228 0530 within this specified period.
AGM on Friday, 26 June 2020, 10.30 a.m. Singapore time	Shareholders/Investors to log-in/dial-in to the AGM using the details received in the Confirmation Email: (a) click on the link in the Confirmation Email and enter the user ID and password to access the "live" audio-visual webcast of the AGM proceedings; or (b) call the telephone number and enter the conference code in the Confirmation Email to access the "live" audio-only stream of the AGM proceedings.

DOCUMENTS AND INFORMATION RELATING TO THE AGM

Documents and information relating to the AGM (including the Annual Report 2019, Notice of AGM (including the letters to Shareholders set out as Appendix A and Appendix B to the Notice of AGM), Proxy Form, Additional Information on Directors Seeking Re-election (as at 12 May 2020) and Shareholding Statistics (as at 12 May 2020)) have been published on SGXNET (<https://www.sgx.com>) and the Company's website (<https://www.rafflesmedicalgroup.com/investor-relations/upcoming-events/annual-general-meeting>). Printed copies of these documents will not be sent to Shareholders/Investors.

In view of the rapidly evolving COVID-19 situation, Shareholders/Investors should note that the manner of conduct of the AGM may be subject to further changes at short notice. Shareholders/Investors are advised to check SGXNET and the Company's website regularly for updates.

Notice of Annual General Meeting

NOTICE IS HEREBY GIVEN that the 31st Annual General Meeting (“**AGM**”) of Raffles Medical Group Ltd (the “**Company**”) will be convened and held by electronic means on **Friday, 26 June 2020 at 10.30 a.m.** for the purpose of considering and, if thought fit, passing with or without modification, the following resolutions as Ordinary Resolutions:

AS ORDINARY BUSINESS

1. To receive and adopt the Directors’ Statement and Audited Financial Statements for the year ended 31 December 2019 together with the Auditors’ Report thereon. **[Resolution 1]**
2. To declare a one-tier tax exempt final dividend of 2.0 Singapore cents per share for the year ended 31 December 2019 (2018: 2.0 Singapore cents per share). **[Resolution 2]**
3. To approve Directors’ Fees (S\$483,000) for the year ended 31 December 2019 (2018: S\$463,000). **[Resolution 3]**
4. To re-elect Dr Loo Choon Yong, who is retiring by rotation in accordance with Regulation 93 of the Constitution of the Company, and who, being eligible, will offer himself for re-election. **[Resolution 4]**
5. To re-elect Mr Koh Poh Tiong, who is retiring by rotation in accordance with Regulation 93 of the Constitution of the Company, and who, being eligible, will offer himself for re-election. **[Resolution 5]**
6. To re-elect Mr Kee Teck Koon, who is retiring by rotation in accordance with Regulation 93 of the Constitution of the Company, and who, being eligible, will offer himself for re-election. **[Resolution 6]**
7. To re-elect Mr Raymond Lim Siang Keat, who is retiring in accordance with Regulation 93 of the Constitution of the Company, and who, being eligible, will offer himself for re-election. **[Resolution 7]**
8. To re-appoint KPMG LLP as Auditors of the Company and to authorise the Directors to fix their remuneration. **[Resolution 8]**

AS SPECIAL BUSINESS

9. Authority to Allot and Issue Shares

That pursuant to Section 161 of the Companies Act (Chapter 50, of Singapore) (“**Companies Act**”) and Rule 806 of the Listing Manual of the Singapore Exchange Securities Trading Limited (“**SGX-ST**”), authority be and is hereby given to the Directors of the Company to:

- (a) (i) allot and issue shares and convertible securities in the capital of the Company whether by way of rights, bonus or otherwise; and/or
- (ii) make or grant offers, agreements or options (collectively, “**Instruments**”) that might or would require shares to be issued, including but not limited to the creation and issue of (as well as adjustments to) warrants, debentures or other instruments convertible into shares,

at any time and upon such terms and conditions and for such purposes and to such persons as the Directors may in their absolute discretion deem fit; and

- (b) (notwithstanding that the authority conferred by this Resolution may have ceased to be in force) issue shares and convertible securities in pursuance of any Instrument made or granted by the Directors while this Resolution was in force,

Notice of Annual General Meeting

9. Authority to Allot and Issue Shares (Cont'd)

Provided That:

- (1) the aggregate number of shares to be issued pursuant to this Resolution (including shares to be issued in pursuance of Instruments made or granted pursuant to this Resolution) does not exceed 50% of the total number of issued shares (excluding treasury shares and subsidiary holdings) in the capital of the Company (as calculated in accordance with sub-paragraph (2) below), of which the aggregate number of shares and convertible securities to be issued other than on a pro-rata basis to shareholders of the Company (including shares to be issued in pursuance of Instruments made or granted pursuant to this Resolution) does not exceed 20% of the total number of issued shares (excluding treasury shares and subsidiary holdings) in the capital of the Company (as calculated in accordance with sub-paragraph (2) below);
- (2) (subject to such manner of calculation as may be prescribed by the SGX-ST) for the purpose of determining the aggregate number of shares that may be issued under sub-paragraph (1) above, the percentage of issued shares shall be based on the total number of issued shares (excluding treasury shares and subsidiary holdings) in the capital of the Company at the time this Resolution is passed, after adjusting for:
 - (i) new shares arising from the conversion or exercise of convertible securities;
 - (ii) new shares arising from the conversion or exercise of any convertible securities or share options or vesting of share awards, which are outstanding or subsisting at the time this Resolution is passed; and
 - (iii) any subsequent bonus issue or consolidation or sub-division of shares.
- (3) in exercising the authority conferred by this Resolution, the Company shall comply with the provisions of the Listing Manual of the SGX-ST for the time being in force (unless such compliance has been waived by the SGX-ST) and the Constitution for the time being of the Company; and
- (4) (unless revoked or varied by the Company in general meeting) the authority conferred by this Resolution shall continue in force until the conclusion of the next AGM of the Company or the date by which the next AGM of the Company is required by law to be held, whichever is the earlier. **[Resolution 9]**

10. Authority to Allot and Issue Shares Under the Raffles Medical Group (2010) Share Option Scheme

That the Directors of the Company be and are hereby authorised to allot and issue or deliver from time to time such number of Shares required pursuant to the exercise of the Options under the Raffles Medical Group (2010) Share Option Scheme.

[Resolution 10]

11. The Proposed Renewal of Share Buy Back Mandate

That:

- (a) for the purposes of Sections 76C and 76E of the Companies Act, the exercise by the Directors of all the powers of the Company to purchase or otherwise acquire fully paid issued ordinary shares in the capital of the Company ("**Shares**"), not exceeding the Maximum Percentage (as defined below), at such price or prices as may be determined by the Directors from time to time up to the Maximum Price (as defined below), whether by way of:
 - (i) on-market purchase of Shares ("**On-Market Share Buy Back**"), transacted on the SGX-ST through the ready market or the special trading counter on SGX-ST trading system or on any other securities exchange on which the Shares may for the time being be listed and quoted ("**Other Exchange**"), through one or more duly licensed stock brokers appointed by the Company for the purpose; and/or

Notice of Annual General Meeting

11. The Proposed Renewal of Share Buy Back Mandate (cont'd)

- (ii) off-market purchase of Shares (“**Off-Market Equal Access Share Buy Back**”) (if effected otherwise than on the SGX-ST or, as the case may be, Other Exchange) in accordance with any equal access scheme(s) as may be determined or formulated by the Directors as they consider fit, which scheme(s) shall satisfy all the conditions prescribed by the Companies Act,

and otherwise be in accordance with all other laws and regulations and rules of the SGX-ST or, as the case may be, Other Exchange as may for the time being be applicable, be and is hereby authorised and approved generally and unconditionally (the “**Share Buy Back Mandate**”);

- (b) unless varied or revoked by Shareholders in a general meeting, the authority conferred on the Directors pursuant to the Share Buy Back Mandate may be exercised by the Directors at any time and from time to time during the period commencing from the date of the passing of this Resolution and expiring on the earlier of:

- (i) the date on which the next AGM of the Company is held or required by law to be held;
- (ii) the date on which the purchases or acquisitions of Shares pursuant to the proposed Share Buy Back Mandate are carried out to the full extent mandated; or
- (iii) the date on which the authority conferred by the proposed Share Buy Back Mandate is revoked or varied by the Shareholders in a general meeting;

- (c) in this Resolution:

“**Average Closing Market Price**” means the average of the closing market prices of the Shares over the last five (5) Market Days, on which transactions in the Shares were recorded, immediately preceding the date of an On-Market Share Buy Back by the Company or, as the case may be, the date of the making of the offer pursuant to the Off-Market Equal Access Share Buy Back, and deemed to be adjusted, in accordance with the Listing Manual, for any corporate action that occurs during the relevant five (5) Market Days and the day on which the repurchase is made;

“**date of the making of the offer**” means the date on which the Company announces its intention to make an offer for an Off-Market Equal Access Share Buy Back, stating the purchase price (which shall not be more than five per cent (5%) above the Average Closing Market Price of the Shares, excluding related expenses) for each Share and the relevant terms of the equal access scheme for effecting the Off-Market Equal Access Share Buy Back;

“**Maximum Percentage**” means the number of issued Shares representing ten per cent (10%) of the issued Shares as at the date of the passing of this Resolution (excluding treasury shares and subsidiary holdings); and

“**Maximum Price**” in relation to a Share to be purchased or acquired, means the purchase price (excluding brokerage, commission, stamp duties, applicable goods and services tax and other related expenses) which shall not exceed more than five per cent (5%) of the Average Closing Market Price of the Share (in the case of an On-Market Share Buy Back or an Off-Market Equal Access Share Buy Back); and

- (d) the Directors of the Company and/or any of them be and are hereby authorised to complete and do all such acts and things (including executing such documents as may be required) as they and/or he/she may consider expedient or necessary to give effect to the transactions contemplated and/or authorised by this Resolution. **[Resolution 11]**

Notice of Annual General Meeting

12. Authority to Issue Ordinary Shares Pursuant to the Raffles Medical Group Ltd Scrip Dividend Scheme

That authority be and is hereby given to the Directors of the Company to allot and issue from time to time such number of ordinary shares as may be required to be allotted and issued pursuant to the Raffles Medical Group Ltd Scrip Dividend Scheme.

[Resolution 12]

13. The Proposed Adoption of the Raffles Medical Group (2020) Performance Share Plan

THAT:

- (a) the share incentive scheme to be named the “Raffles Medical Group (2020) Performance Share Plan” (the “**RMG PSP 2020**”), details of which are set out in the letter to Shareholders dated 4 June 2020, which is appended to this Notice of AGM as Appendix B (“**Appendix B**”), be and is hereby approved and adopted; and
- (b) the Directors of the Company be and are hereby authorised:
 - (i) to establish and administer the RMG PSP 2020;
 - (ii) to modify and/or amend the RMG PSP 2020 from time to time provided that such modifications and/or amendments are effected in accordance with the Rules of the RMG PSP 2020 and to do all such acts and to enter into all such transactions, arrangements and agreements as may be necessary or expedient in order to give full effect to the RMG PSP 2020;
 - (iii) to grant awards (the “**Awards**”) in accordance with the Rules of the RMG PSP 2020 and to allot and issue or deliver from time to time such number of Shares required pursuant to the vesting of the Awards under the RMG PSP 2020; and
 - (iv) to complete and do all acts and things (including executing such documents as may be required) as they may consider necessary, desirable or expedient for the purposes of or to give effect to this resolution as they think fit and in the interests of the Company.

[Resolution 13]

14. The Proposed Adoption of the Raffles Medical Group (2020) Share Option Scheme

THAT:

- (a) the share incentive scheme to be named the “Raffles Medical Group (2020) Share Option Scheme” (the “**RMG ESOS 2020**”), details of which are set out in Appendix B, be and is hereby approved and adopted; and
- (b) the Directors be and are hereby authorised:
 - (i) to establish and administer the RMG ESOS 2020;
 - (ii) to modify and/or amend the RMG ESOS 2020 from time to time provided that such modifications and/or amendments are effected in accordance with the Rules of the RMG ESOS 2020 and to do all such acts and to enter into all such transactions, arrangements and agreements as may be necessary or expedient in order to give full effect to the RMG ESOS 2020;
 - (iii) to grant options (the “**Options**”) in accordance with the Rules of the RMG ESOS 2020 and to allot and issue or deliver from time to time such number of Shares required pursuant to the exercise of the Options under the RMG ESOS 2020; and
 - (iv) to complete and do all acts and things (including executing such documents as may be required) as they may consider necessary, desirable or expedient for the purposes of or to give effect to this resolution as they think fit and in the interests of the Company.

[Resolution 14]

Notice of Annual General Meeting

15. The Proposed Grant of Options at a Discount under the Raffles Medical Group (2020) Share Option Scheme

THAT subject to and contingent upon the passing of Resolution 14, the Directors be and are hereby authorised to grant Options in accordance with the Rules of the RMG ESOS 2020 with exercise prices set at a discount to the Market Price, provided that such discount does not exceed the relevant limits set by the SGX-ST. **[Resolution 15]**

BY ORDER OF THE BOARD

Kimmy Goh
Company Secretary
4 June 2020

Notice of Annual General Meeting

Explanatory Notes:

In relation to Ordinary Resolution 2 above, the Company will, upon the approval of the Shareholders of the proposed final dividend for the year ended 31 December 2019, announce the record date and payment date in due course.

Ordinary Resolution 3 above, if passed, is to seek approval for the payment of up to S\$483,000 to all Directors as Directors' Fees for the year ended 31 December 2019.

In relation to Ordinary Resolution 4 above, Dr Loo Choon Yong will, upon re-election as Director of the Company, continue to serve as the Executive Chairman of the Company. Dr Loo is the father of Dr Sarah Lu Qinghui, an Executive Director of the Company.

In relation to Ordinary Resolution 5 above, Mr Koh Poh Tiong will, upon re-election as Director of the Company, remain as the Lead Independent Director and as a member of the Audit & Risk Committee as well as the Nomination & Compensation Committee. He is considered an Independent Director. There are no relationships (including immediate family relationships) between Mr Koh and the other Directors of the Company.

In relation to Ordinary Resolution 6 above, Mr Kee Teck Koon will, upon re-election as Director of the Company, remain as the Chairman of the Audit & Risk Committee. He is considered an Independent Director. There are no relationships (including immediate family relationships) between Mr Kee and the other Directors of the Company.

In relation to Ordinary Resolution 7 above, Mr Raymond Lim Siang Keat will, upon re-election as Director of the Company, remain as a member of the Audit & Risk Committee. He is considered an Independent Director. There are no relationships (including immediate family relationships) between Mr Lim and the other Directors of the Company.

Ordinary Resolution 9 above, if passed, will authorise the Directors of the Company from the date of the above AGM until the date of the next AGM to allot and issue shares and convertible securities in the Company up to an amount not exceeding in total 50% of the total number of issued shares (excluding treasury shares and subsidiary holdings) in the capital of the Company, for the time being for such purposes as they consider would be in the interest of the Company, provided that the aggregate number of shares to be issued other than on a pro-rata basis to existing shareholders pursuant to this Resolution shall not exceed 20% of the total number of issued shares (excluding treasury shares and subsidiary holdings) in the capital of the Company, for the time being.

Ordinary Resolution 10 above, if passed, will authorise the Directors to allot and issue or deliver from time to time such number of shares in the capital of the Company pursuant to the exercise of the options under the RMG ESOS 2010.

Ordinary Resolution 11 above, if passed, will renew the Share Buy Back Mandate to permit the Company to purchase or otherwise acquire its issued ordinary shares on the terms and subject to the conditions of the Resolution. Further details are set out in the letter to shareholders dated 4 June 2020, which is appended as Appendix A to the Notice of AGM ("**Appendix A**"). Appendix A can be downloaded from the Company's website at <https://www.rafflesmedicalgroup.com/investor-relations/upcoming-events/annual-general-meeting>. All capitalised terms used in Resolution 11 which are not defined herein shall have the same meanings ascribed to them in Appendix A, unless otherwise defined herein or where the context otherwise requires.

Ordinary Resolution 12 above, if passed, will authorise the Directors of the Company to issue ordinary shares pursuant to the Raffles Medical Group Ltd Scrip Dividend Scheme to members who have elected to receive scrip in lieu of cash in respect of any dividend to which the said Scrip Dividend Scheme is applied.

Further details in relation to Ordinary Resolutions 13 to 15 are set out in the letter to shareholders dated 4 June 2020, which is appended as Appendix B to the Notice of AGM ("**Appendix B**"). Appendix B can be downloaded from the Company's website at <https://www.rafflesmedicalgroup.com/investor-relations/upcoming-events/annual-general-meeting>. All capitalised terms used in Resolutions 13 to 15 which are not defined herein shall have the same meanings ascribed to them in Appendix B, unless otherwise defined herein or where the context otherwise requires.

Notes:

Appointment of Proxy and Voting

1. In compliance with the Order and the Joint Guidance, a Shareholder who wishes to vote at the AGM can only do so by appointing the Chairman of the AGM to act as his/her/its proxy to vote on his/her/its behalf in respect of all the Shares held by him/her/it. In the Proxy Form, a Shareholder should specifically direct the Chairman of the AGM as proxy on how he is to vote for or vote against (or abstain from voting on) the resolutions to be tabled at the AGM. If no specific direction as to voting on a given resolution is given, the appointment of the Chairman of the AGM as proxy for that resolution shall be treated as invalid. All valid votes cast via proxy on each resolution will be counted.
2. Investors holding Shares through relevant intermediaries (as defined under Section 181 of the Companies Act (Chapter 50 of Singapore)), including CPF/SRS Investors, should not use the Proxy Form and should contact their relevant intermediaries as soon as possible to specify voting instructions. CPF/SRS Investors should approach their respective CPF Agent Banks or SRS Operators by **Tuesday, 16 June 2020, 5.00 p.m. Singapore time** to ensure that their votes are submitted.
3. Personal Data Privacy: By submitting an instrument appointing the Chairman of the AGM as proxy to attend, speak and vote at the AGM and/or any adjournment thereof, a member of the Company consents to the collection, use and disclosure of the member's personal data by the Company (or its agents) for the purpose of the processing and administration by the Company (or its agents) of the appointment of the Chairman of the AGM as proxy for the AGM (including any adjournment thereof) and the preparation and compilation of the attendance lists, minutes and other documents relating to the AGM (including any adjournment thereof) recordings and transmitting images and/or voice recordings when broadcasting the AGM proceedings through webcast and in order for the Company (or its agents) to comply with any applicable laws, listing rules, regulations and/or guidelines.

Website

The Company's website, <https://www.rafflesmedicalgroup.com/investor-relations/upcoming-events/annual-general-meeting>, provides more information about the Company, including the latest Annual Report, the Notice of AGM, Appendices A and B to the Notice of AGM, the Proxy Form, Additional Information on Directors Seeking Re-election (as at 12 May 2020) and Shareholding Statistics (as at 12 May 2020).